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We examined nine dengue virus-specific human CD4/ CD80 cytotoxic T lymphocyte (CTL) clones for protein recognition,
using recombinant vaccinia viruses which contain genes coding for dengue virus proteins. These clones were established
from peripheral blood mononuclear cells of a donor previously immunized with a live-attenuated experimental dengue-1
vaccine. Of nine CD4/ T cell clones, seven were dengue-1-specific and two were dengue-1–dengue-3 cross-reactive. Four
dengue-1-specific clones and one dengue-1–dengue-3 cross-reactive clone recognized epitopes within the NS1 or NS2a
proteins. Analysis of human leukocyte antigen (HLA) restriction revealed that three dengue-1-specific clones are HLA-DR1-
restricted and one dengue-1–dengue-3 cross-reactive clone is HLA-DPw3-restricted. These results indicate that NS1 and
NS2a proteins as well as C, E, and NS3 proteins reported earlier contain one or more epitopes recognized by dengue virus-
specific human CD4/ T lymphocytes. q 1997 Academic Press
INTRODUCTION cell clones (8–10); however, the T cells from only a small
number of dengue-immune donors have been analyzed
Dengue virus infections are a serious health problem thus far. Analyses of other donors are necessary for fur-
in tropical and subtropical areas of the world (1). Dengue ther understanding the recognition of dengue virus pro-
viruses are members of the family Flaviviridae and are teins by human T lymphocytes.
transmitted by Aedes aegypti mosquitoes. There are four We have previously reported CD4/ cytotoxic T cell
serotypes, types 1, 2, 3, and 4 (2). Protective immunity to responses in a recipient of an experimental live-attenu-
the homotypic serotype is believed to be life-long, but ated dengue virus type 1 (dengue 1) vaccine (11). Periph-
that to heterologous dengue virus serotypes is short- eral blood mononuclear cells (PBMC) were obtained after
lived (3). Epidemiologic studies have demonstrated that vaccination with an experimental live-attenuated dengue
the majority of cases of the more severe form of dengue 1 virus vaccine (dengue 1 45AZ5 PDK passage 27). Prep-
illness, dengue hemorrhagic fever (DHF), occur following aration of the vaccine and clinical observations after vac-
secondary dengue virus infection with a serotype heterol- cination have been reported (11, 12). We demonstrated
ogous to that of the primary infection (4). that this individual had a predominantly serotype-specific
We have been analyzing dengue virus-specific T cell CTL response by bulk culture and clonal analysis and
responses in order to understand the role of T lympho- that there was a high precursor frequency of these den-
cytes in the recovery from infections and in the pathogen- gue-1-specific CTL in the circulation 4 months postvacci-
esis of dengue hemorrhagic fever. Serotype-specific and nation. Approximately 80% of the CD4/ CTL clones gen-
serotype-cross-reactive memory T cells were detected erated were dengue-1-specific, and 20% of the clones
after recovery from natural dengue virus infections or were cross-reactive for dengue 1 and dengue 3. In the
following immunization with live-attenuated dengue virus present study, we examine some of these dengue virus-
vaccines (5 – 7). Proteins recognized by dengue virus- specific CD4/ CTL clones for protein recognition. Five
specific CD4/ CD80 and CD8/ CD40 T cells have of the nine clones recognized epitopes within the NS1
been defined. We have reported that NS3, E, and C pro- or NS2a protein regions. As these clones had different
teins were recognized by dengue virus-specific CD4/ T serotype specificities (dengue-1 serotype specific and
dengue-1/dengue-3 cross-reactive) and different HLA re-
stricting elements, we conclude that there are at least1 Current address: Department of Microbiology, Kinki University
three different types of CD4/ T cell clones which recog-School of Medicine, 377-2 Ohno-higashi, Osaka-sayama, 589 Japan.
nize epitopes located within the NS1 or NS2a proteins2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (508) 856-4890. of the dengue virus.
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TABLE 1MATERIALS AND METHODS
Lysis of Target Cells Expressing NS1 and NS2a by DengueViruses
Virus-Specific CD4/ Cytotoxic T Cell Clonesa
Dengue virus type 1 (Hawaii) was provided by Walter
Percentage of specific 51 CrE. Brandt (Walter Reed Army Institute of Research). De-
releaseb (CD4/ CTL clones)
tails of the preparation of the dengue-vaccinia virus
recombinants have been previously described (13). Target cells infected with 1 6 14 18 27
vP838 contains genes coding for 15 amino acids (aa)
Experiment 1of E, NS1, and NS2a and NS2b of dengue-1 virus, vP841
vP 838 (15 a.a. E-NS1-NS2a-NS2b) 66 81 89 62 85contains genes coding for 15 aa of E, NS1, and NS2a
vP 841 (15 a.a. E-NS1-NS2a) 64 70 72 58 84
of dengue-1 virus, and vP1027 contains genes coding vP 1027 (20 a.a. C-prM-E) 0 4 0 12 0
for 20 aa of C, prM, and E of dengue-1 virus. vP452 is a vP 452 (Control) 3 0 0 5 5
Experiment 2parental vaccinia virus which does not contain dengue
vP 838 (15 a.a. E-NS1-NS2a-Ns2b) 71 NDc 93 76 NDvirus genome.
vP 841 (15 a.a. E-NS1-NS2a) 61 83 83 79 ND
vP 1027 (20 a.a. C-prM-E) 0 6 14 3 ND
Establishment of dengue virus-specific T cell clones vP 452 (Control) 8 1 12 6 ND
by limiting dilution
a 103 Target cells were incubated with effector cells for 5 hr.
Dengue virus-specific T cell clones were established b Effector:target cell ratio was 20:1 for clones 1, 14, 18, 27, and 8:1
as previously reported (11). Briefly, PBMC which had for clone 6 in experiment 1, and 15:1 for clone 1, 6:1 for clone 6, 8:1
for clone 14, and 4:1 for clone 18 in experiment 2. Underlines indicatebeen stimulated in bulk culture with live dengue-1 virus
significant levels of lysis.for 7 days were collected and plated in 96-well round
c ND, not done.bottom plates at a concentration of 1, 3, 10, and 100 cells
per well in AIM-V medium (GIBCO Laboratories, Grand
Island, NY) containing 10% pooled human AB serum, 10% RESULTS
T cell growth factor, 105 g-irradiated (3,500 rads) autolo-
Recognition of nonstructural proteins NS1-2a bygous PBMC, and 1:3-diluted dengue virus type 1. Cells
CD4/ T cell cloneswere stimulated on Days 7, 14, 21, and every 10 to 14
days thereafter. Growing cells were transferred to 48- Nine dengue virus-specific CD4/ CTL clones were
well flat bottom plates and cultured with 106 g-irradiated examined for cytotoxic activity against autologous LCL
PBMC. infected with vP838, vP841, vP1027, or vP452. Clones 1,
5, 6, 7, 14, 20, and 27 were specific for dengue-1, clones
Preparation of target cells 10 and 18 were cross-reactive for dengue-1 and dengue-
3, as previously described (11). Clones 1, 6, 14, 18, andAutologous Epstein–Barr virus (EBV)-transformed B
27 lysed target cells infected with vP838 or vP841, butlymphoblastoid cell lines (LCL) were established as pre-
did not lyse target cells infected with vP1027 or vP452viously described (11). LCL were infected with recombi-
(Table 1). These results indicate that clones 1, 6, 14, 18,nant dengue-vaccinia viruses at an m.o.i. of 10  20
and 27 recognize an epitope(s) on NS1 or NS2a. ClonesPFU/cell and incubated at 377 for 16–20 hr. Target cells
5, 7, 10, and 20 lysed dengue 1 antigen-pulsed targetwere labeled with 0.25 mCi of 51Cr(Na2CrO4), washed and
cells, but did not lyse target cells infected with any of theresuspended at 1 1 104 cells per milliliter for use in
four recombinant vaccinia viruses (data not presented).cytotoxicity assays.
HLA restriction of the lysis of target cells by CD4/ TCytotoxicity assays
cell clones
Target cells (prepared as above) were plated at 1 1 HLA restriction of the lysis of target cells by five CD4/
103 cells per well in 0.1 ml RPMI plus 10% FCS in V- T cell clones which recognize NS1.2a was examined
bottom microtiter plates. Effector cells were added at using allogeneic target cells infected with vP841 or vP838
different concentrations in triplicate in 0.1 ml of medium (Table 2). We infer that dengue-1 and dengue-3 cross-
containing 10% FCS. Following centrifugation (200 g for reactive clone 18 is HLA-DPw3-restricted and dengue-1-
5 min) the plates were incubated at 377 for 5 hr. Following specific clones 6, 14, and 27 are HLA-DR1-restricted.
incubation, supernatant fluids were harvested and HLA restriction of clone 1 could not be determined.
counted in an automatic gamma counter. The percentage
of specific 51Cr release was calculated by the formula:
DISCUSSION
[(cpm experimental release 0 cpm spontaneous re-
lease)/(cpm maximal release 0 cpm spontaneous re- In the present study we have shown that five of nine
dengue virus-specific human CD4/ CTL clones recog-lease)] 1 100.
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TABLE 2
Determination of HLA Class II Restriction of CD4/ CTL Clones Which Recognize Epitope(s) on NS1 or NS2aa
HLA Class II Typeb Percentage of specific 51 Cr Releasec
Targeta DR DR DP DQ 1 6 14 18 27
Experiment 1
Autologous 1/W6 W52 W3/W4 W1 66 29 81 71 64
9022 W17 W52 W3 W2 6 4 22 60 12
9038 W12 W52 W2 W7 0 0 7 6 14
9087 3 W52 W3/W4 W2 3 2 4 57 4
CB 7 W53 W4 W2 10 12 17 5 10
Experiment 2
Autologous 1/W6 W52 W3/W4 W1 64 61 36 33 9
9011 W15 — d W2/W4 W6(W1) 7 6 2 7 3
9052 7 W53 W4 W9 7 4 6 4 1
3107 2 — W4 W2 0 0 0 0 0
CB 7 W53 W4 W2 2 0 3 0 0
MS 1/4 W53 W4 W1/W3 4 71 51 4 23
Experiment 3
Autologous 1/W6 W52 W3/W4 W1 65 47 69 70 NDe
9011 W15 — W2/W4 W6(W1) 0 3 0 0 ND
9038 W12 W52 W2 W7 0 7 3 9 ND
9087 3 W52 W3/W4 W2 0 ND 14 60 ND
9004 1 — W4 W2 ND 46 ND ND ND
CB 7 W53 W4 W2 ND 2 ND ND ND
CP 5/7 W52/W53 W4 W2/W3 ND 1 ND ND ND
a Autologous and allogeneic LCL infected with VP841 were used as target cells in experiments 1 and 2, and those infected with VP838 were
used in experiment 3. 103 target cells were incubated with effector cells for 5 hr.
b Known HLA loci which match donor HLA are underlined.
c Effector:target cell ratio was 20:1 for clones 1, 14, and 8, 5:1 for clone 6, and 9:1 for clone 27 in experiment 1; 11:1 for clone 1, 7:1 for clone 6,
14:1 for clone 14, 10:1 for clone 18, 20:1 for clone 27, and 10:1 for clones 1, 6, 14, and 18 in experiment 3. Underlines indicate significant levels of
lysis.
d —, locus for which HLA type is not known.
e ND, not done.
nized NS1 or NS2a protein. Bulk culture analysis of this protein is a nonglycosylated protein which consists of
218 amino acids (17, 18). The precise function of theindividual’s PBMC revealed CD4/ CTL killing of NS1.2a-
expressing target cells, as well as CD4/ and CD8/ NS1 protein is uncertain although a role in viral RNA
replication has been suggested (19). The role of the NS2akilling of C.prM.E-expressing target cells (14). However,
in bulk culture experiments, only dengue-1 serotype-spe- protein is not known. It has been reported that immuniza-
tion of mice with dengue NS1 protein protects mice fromcific CTL responses were seen (14, 15). In the present
study, of five CD4/ T cell clones analyzed, four were lethal challenge with dengue virus as does passive im-
munization with monoclonal antibodies to NS1 (20, 21).dengue-1 specific and one was dengue-1–dengue-3
cross-reactive. These results suggest that there are one Dengue virus-serotype cross-reactive murine CD4/ and
CD8/ CTL clones which recognize epitope(s) on the NS1or more epitopes recognized by human CD4/ T cells
within the proteins NS1 and/or NS2a. or NS2a proteins have been reported (22). Immunization
of mice with a recombinant vaccinia virus construct con-The serotype specificity, protein recognition, and HLA
restriction patterns of T cell clones 6, 14, and 27 are the taining NS1.2a which expresses authentic dengue virus
NS1 conferred 100% protection; immunization with con-same. It is possible that these clones originated from the
same T cell clone in vivo as the culture was expanded structs which contained NS1 and only partial sequences
of the NS2a protein conferred partial protection. This mayprior to limiting dilution. However, it has been shown that
dengue virus-specific T cell clones which have the same have been due to aberrant NS1 forms produced in the
absence of complete NS2a protein (23–25). In these ani-epitope recognition and HLA restriction may originate
from different original T cell clones as demonstrated by mal model challenge systems, NS1 antibodies were de-
tected, but CTL responses were not tested.differing T cell receptor usage (16). In the present study,
we did not perform T cell receptor sequencing. In the human system, we have reported that NS3 and
E proteins contain epitopes recognized by dengue virus-The NS1 protein of dengue-1 virus is a glycosylated
protein which consists of 352 amino acids, and the NS2a specific human CD4/ T cells (7, 8). We have recently
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virus-specific human CD4/ T-lymphocyte responses in a recipi-determined that dengue virus-specific CD4/ CTL clones
ent of an experimental live-attenuated dengue virus type 1 vac-established from the PBMC of a dengue 4-immune donor
cine: Bulk culture proliferation, clonal analysis, and precursor
recognize C protein (10). The results shown in the pres- frequency determination. J. Virol. 67(10), 5962–5967.
ent paper, along with our previous reports, strongly sug- 12. Edelman, R., Tacket, C. O., Wasserman, S. S., Vaughn, D. W., Eck-
els, K. H., Dubois, D. R., Summers, P. L., and Hoke, C. H. (1994).gest that the predominant proteins recognized by dengue
A live attenuated dengue-1 vaccine candidate (45AZ5) passagedvirus-specific CD4/ T cells may differ depending on the
in primary dog kidney cell culture is attenuated and immuno-individual or the infecting dengue virus serotype and that
genic for humans. J. Infect. Dis. 170, 1448–1455.
NS1 and/or NS2a may contain dominant T cell epitopes 13. Fonseca, B. A. L., Pincus, S., Shope, R. E., Paoletti, E., and Mason,
in humans with certain HLA haplotypes. The heterogene- P. W. (1994). Recombinant vaccinia viruses co-expressing den-
gue-1 glycoproteins prM and E induce neutralizing antibodiesity in protein recognition of dengue virus-specific human
in mice. Vaccine 12(3), 279–285.CD4/ T cells has an important implication for the future
14. Mathew, A., Kurane, I., Rothman, A. L., Zeng, L.-L., Brinton, M. A.,development of subunit vaccines.
and Ennis, F. A. (1996). Dominant recognition by human CD8/
cytotoxic T lymphocytes of dengue virus nonstructural proteins
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